New Committee Members

At our last managing committee meeting, the AHPPI welcomed the following new committee members.

We are very fortunate to have them on the team and look forward to working with them.


Dr Muna Albayaty

Medical Director, PAREXEL, London

Muna is a Consultant Specialist in Pharmaceutical Medicine with 12 years of experience in early phase clinical drug development and clinical trials as PI. She is a Fellow of the Faculty of Pharmaceutical Medicine and her main areas of interest are Respiratory, CNS and Immunology.


Dr Jim Bush

Medical Director, Covance, Leeds

Jim has worked at Covance’s Phase I Unit for over 6 years. Prior to that he spent over 7 years at Renovo, a biopharmaceutical company, where he was the Vice President of Surgery and Deputy QPPV. Jim gained his MBChB and PhD in medicine from Manchester, he is a Member of the Royal College of Surgeons (Edinburgh), a member of the RPM, holds a diploma in Pharmaceutical Medicine and a Certificate of Completion of Training in Pharmaceutical Medicine.


Dr Joseph Cheriyan

Consultant Clinical Pharmacologist and Physician, Cambridge University Hospital, Cambridge

Joseph has been a consultant since 2006, working in the NHS and the University – running academic and industry sponsored Phase I/II clinical trials. He also has a 50% secondment (non-employee status) to GSK’s Phase I/II clinical unit at Addenbrooke’s Hospital in Cambridge – GSK’s last remaining early phase clinical research facility in the world.


Anthea Cromie PhD

Senior Director, Clinical Pharmacology Sciences, Celerion, Belfast

Anthea has over 20 years of experience in early clinical research. In her current role she oversees study design, data analysis, interpretation and reporting of early phase clinical pharmacology studies, and is also responsible for ensuring European standards and regulatory requirements are an integral part of the harmonised global processes within Celerion’s global Clinical Pharmacology Sciences group.


Dr Annelize Koch

Medical Director, Simbec Research Ltd, Merthyr Tydfil

Annelize has over 15 years of experience in drug development, including interpretation of preclinical pharmacology & toxicology, running & planning Phase I (including FIH) and Phase IIa trials. In addition to her medical degree, Annelize holds a Certificate of Completion of Training in Pharmaceutical Medicine (RCP) and is a Fellow of the FPM.


Dr Stuart Mair

Medical Director at Quotient Clinical, Nottingham

Stuart joined Quotient in 2009 and before that he was Medical Director at Charles River’s Phase I unit in Edinburgh (formerly Inveresk Research). He currently leads a team of 12 medical doctors at Quotient and also acts as a Principal Investigator on a range of studies including first-in-human studies. He is also a member of the ABPI Experimental Medicine Expert Network (EMEN) committee and is a Fellow of the FPM.

 


Dr Jörg Täubel

CEO, Richmond Pharmacology, London

Jörg Täubel is a medical practitioner and clinical pharmacologist with a special interest in cardiology. Jörg co-founded Richmond Pharmacology and as well as being the CEO he is also a Principal Investigator and Responsible Officer for training and revalidation of the Medical Doctors employed at the unit.


For a full list of current committee members, please click this link.

Comments Off on New Committee Members

Exploratory Medicines Development: Innovation And Risk Management, London, May 2017 – one week away

Logo Eufemed 10-6-'15


Joint Meeting of European Human Pharmacological Societies

17 May – 19 May, 2017, London

You still have time to register for the EUFEMED 2017 conference – Exploratory Medicines Development: Innovation And Risk Management.


The Faculty of Pharmaceutical Medicine has approved this event for Continuing Professional Development (CPD)


  • Pre-conference workshop – link
  • Conference programme – link
  • Registration page – link

All abstracts will be published in Frontiers in Pharmacology. This is the #2 most cited open-access journal in pharmacology and pharmacy, with an impact factor of 4.418.


The pre-conference workshop will be followed by a welcome reception and opportunity to register for the conference itself, even if you don’t attend the workshop.


The conference dinner will be at the Museum of London.


Members of AHPPI get substantial savings on the non-member prices.

We hope to meet you there!

The AHPPI Committee.

conferenceart

Comments Off on Exploratory Medicines Development: Innovation And Risk Management, London, May 2017 – one week away

Abstract and Bursary deadlines 31-Jan-2017: Big Data & the Development of New Medicines


ITMAT in Edinburgh

Big Data & the Development of New Medicines

Friday 17 March 2017, Edinburgh, UK

 

Registration and abstract submission are open for the Institute for Translational Medicine & Therapeutics (ITMAT) in Edinburgh Meeting, which will be held on ‘Big Data & the Development of New Medicines’ on Friday 17 March 2017 at the Royal College of Physicians of Edinburgh conference centre.

The one-day programme will bring together a faculty of internationally-recognised speakers, thanks to support from the British Pharmacological Society and the Royal Society of Edinburgh. The organisers look forward to welcoming both early and established researchers, from across science and medicine.

Meeting organisers

  • Dr Neeraj Dhaun, British Heart Foundation Intermediate Clinical Research Fellow, University of Edinburgh, UK
  • Professor Garret FitzGerald, Professor of Medicine & Systems Pharmacology & Translational Therapeutics and Director, ITMAT, University of Pennsylvania, USA
  • Professor Sir John Savill, Chief Executive, Medical Research Council, UK and Professor of Experimental Medicine, Vice Principal and Head of College of Medicine & Veterinary Medicine, University of Edinburgh, UK
  • Professor David Webb, President, British Pharmacological Society and Christison Professor of Therapeutics & Clinical Pharmacology, University of Edinburgh, UK

Further information about registration and the programme is available www.bps.ac.uk/ITMAT.

Registration fees 

Register online.

Abstract submission deadline: 31 January 

Full details about how to submit your research before the deadline are available online.

Bursary application deadline: 31 January

Applications are welcome from members of the British Pharmacological Society who have submitted research for presentation at the ITMAT Meeting. Further details about the application process and criteria are available online (member sign in required).

About ITMAT 

This is the first time that the ITMAT Meeting has been held in Europe: ITMAT is directed by Professor Garret FitzGerald HonFBPhS and based at the Perelman School of Medicine, University of Pennsylvania, and was the first institute for translational medicine in the world. It supports work at the interface of basic and clinical research, focusing on developing new and safer medicines.

Please do not hesitate to contact the Society’s Meetings Team (meetings@bps.ac.uk / +44 (0)20 7239 0183) if you have any questions.

Best wishes,

David Webb MD DSc FRSE FMedSci PBPhS
President, British Pharmacological Society

Comments Off on Abstract and Bursary deadlines 31-Jan-2017: Big Data & the Development of New Medicines

Big Data & the Development of New Medicines


ITMAT in Edinburgh

Big Data & the Development of New Medicines

Friday 17 March 2017, Edinburgh, UK

Registration has begun for the Institute for Translational Medicine & Therapeutics (ITMAT) in Edinburgh Meeting, which will be held on the theme of ‘Big Data & the Development of New Medicines’ on Friday 17 March 2017 at the Royal College of Physicians of Edinburgh conference centre.

The organisers look forward to welcoming attendees from the UK and Europe, both early and established researchers, from across science and medicine. Book your place for what promises to be an exciting and engaging meeting.

This is the first time that the ITMAT Meeting has been held in Europe: ITMAT is directed by Dr Garret FitzGerald and based at the Perelman School of Medicine, University of Pennsylvania, and was the first institute for translational medicine in the world. It supports work at the interface of basic and clinical research, focusing on developing new and safer medicines.

The one-day programme will bring together a faculty of internationally-recognised speakers, thanks to support from the British Pharmacological Society and the Royal Society of Edinburgh.

Dates for your diary

Abstract submission deadline: 20 January 2017

British Pharmacological Society member bursary deadline: 20 January 2017

Registration deadline: 10 March 2017

Further information about registration and the programme is available www.bps.ac.uk/ITMAT. In addition, you are welcome to contact the Society’s Meetings Team (meetings@bps.ac.uk / +44 (0)20 7239 0176) if you have any questions.

Comments Off on Big Data & the Development of New Medicines

Exploratory Medicines Development: Innovation And Risk Management, London, May 2017 – registration open

Logo Eufemed 10-6-'15


Registration for the EUFEMED 2017 conference – Exploratory Medicines Development: Innovation And Risk Management has now opened.

Members of AHPPI get substantial savings on the non-member prices ranging from £37 (early-bird workshop only) to £103.20 (early-bird workshop and conference) when including VAT.

  • Pre-conference workshop, 17 May – link
  • Conference programme – link
  • Registration page – link

The pre-conference workshop will be followed by a welcome reception and opportunity to register for the conference itself, even if you don’t attend the workshop.

The conference dinner will be at the Museum of London.

A sponsorship and exhibitor pack will be available soon.

Hope to meet you there!

The AHPPI Committee.

conferenceart

Comments Off on Exploratory Medicines Development: Innovation And Risk Management, London, May 2017 – registration open

EUFEMED Clinical Pharmacology Conference, London, May 2017 – Web site goes live!

Logo Eufemed 10-6-'15


Letter from the President:

Dear Colleague,

On behalf of the Organising and Scientific Committees it is our great pleasure to welcome you to the 1st conference of the European Federation for Exploratory Medicines Development (EUFEMED), to be held from May 18 – 19, 2017 in London, United Kingdom.

This conference is the result of a continued joint effort of the founding associations of EUFEMED: BAPU (Belgium), Club Phase 1 (France), AGAH (Germany) and AHPPI (United Kingdom). Indeed, after organising successful joint meetings in Berlin (2011), Nice (2013) and Brussels (2015) we are proud to present to you this exciting scientific program.

Following the tradition of previous conferences, this 2-day meeting provides an excellent opportunity to hear about recent advances in early clinical drug development. To that end a mixture is offered of focused scientific sessions, interactive workshops and open forum panel discussions. Being aware of the importance of safety in exploratory medicines development, the focus of the 2017 meeting is on innovation and risk management in early phase clinical trials.

A 1-day preconference workshop takes place on 17 May and is dedicated to practical aspects of assessing and mitigating risk in early clinical drug development.

It is our intention to offer a stimulating scientific atmosphere in which you can meet old colleagues and make new friends, inspired by the lively city of London.

We welcome you to EUFEMED 2017!

Conference Website

 

Comments Off on EUFEMED Clinical Pharmacology Conference, London, May 2017 – Web site goes live!

Revising the guideline on first-in-human clinical trials

EMA_Logo

The EMA yesterday published a guideline:

Draft guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

The document can be found here.

The consultation period ends 28-Feb-2017.

Comments Off on Revising the guideline on first-in-human clinical trials

Exploratory medicines development – Innovation and risk management

First EUFEMED Conference

Joint Meeting of European Human Pharmacological Societies
Wednesday 17 May – Friday 19 May, 2017, London/UK


Assessment and mitigation of risk are most challenging in exploratory drug development when a promising new compound is to be characterised in early phase clinical trials.

  • How can we make best use of the results from nonclinical studies to better predict the risk in healthy subjects and volunteer patients?
  • How can combined protocols safely and successfully include healthy volunteers and patients in one trial?
  • Can assessment of target engagement via PD markers help to minimise risk in early development?
  • Is physiology-based PK useful to mitigate risk?
  • How do risks differ between biologicals and small molecules?

These and related topics will be addressed by the first conference of the European Federation for Exploratory Medicines Development (EUFEMED) focusing on

Exploratory medicines development – Innovation and risk management

In the tradition of previous Joint Meetings, AHPPI, the AGAH (Germany), Club Phase 1 (France) and BAPU (Belgium) have again connected to present you with state-of-art lectures and break-out groups discussing hands-on solutions.

The conference will take place in the Royal Borough of Kensington and Chelsea at the Kensington Conference Centre.

Details will be available on our website soon.

Please save the date of 17-19 May 2017 now.

Proceedings of last year’s meeting in Brussels can be found here.

Hope to meet you there!

The AHPPI Committee.Logo Eufemed 10-6-'15

Comments Off on Exploratory medicines development – Innovation and risk management

Safety & Regulation in Early Clinical Drug Development, 02-Dec-2016

bapu_logo


The BAPU (Belgian Association of Phase I Units) board is pleased to invite you to the BAPU Symposium: “Safety & Regulation in Early Clinical Drug Development”, which will take place on Friday December 2, 2016 at the Marriot Hotel in Gent.

Please find enclosed the programme, registration information and address. Last registration date is Friday, November 11.

Friday, December 2nd, 2016

  • 12:30 Registration and Coffee
  • 13:30 Introduction by the BAPU Chairman Delphine Malisse

Part I: Safety Aspects in Early Clinical Development

Chair: Jan de Hoon, Annick Van Riel

  • 13:40 What makes FAAH so attractive as a CNS target? From bench to clinic. Mark Schmidt, Johnson & Johnson
  • 14:20 The BIAL 10-2474 Accident: Investigator Site Perspective. Alain Patat, Biotrial, France
  • 15:00 Safety Aspects in Phase I Clinical Research: Regulator’s perspective and Recommendations. Walter Janssens, FAHMP
  • 15:30 Panel discussion. Walter Janssens, Mark Schmidt, Alain Patat, Jan De Hoon
  • 16:00 Coffee Break

Part II: EU Regulation – most recent updates

Chair: Sylvie Rottey

  • 16:30 EU Regulation: Considerations on Implementation and effects on Early Clinical Research. Diane Kleinermans, Ministry of Health
  • 17:15 Discussion. Diane Kleinermans, Sylvie Rottey
  • 17:30 Goodbye and Reception

Programme and registration information

See also the BAPU Web site.


ghent_gent

Comments Off on Safety & Regulation in Early Clinical Drug Development, 02-Dec-2016

AGAH Meeting, Berlin

agah_logoAGAH, the German Association for Applied Human Pharmacology, held its 25th Annual Meeting on 21-22 April in Berlin, which focused on the topic “Exploratory drug development in immunological therapy”.

The first day’s sessions covered a variety of immunological targets inherently related to the cascade of immune response mechanisms before highlighting the monitoring of immunotoxicity and immunogenicity in novel immunological therapies. The sessions on day 2 began with an overview of early clinical trials with vaccines and then concluded by addressing the various challenges faced in immunotherapy, examining lessons learned in the last 10 years.

The presentations can be accessed at the following link.

AGAH is a founding member of EUFEMED (the European Federation for Exploratory Medicines Development) that was formally incorporated in May 2015 and also includes AHPPI, Club Phase 1, and BAPU – the British, French and Belgian professional member associations specialising in human pharmacology.

AGAHBerlin2016


Written by John Horkulak, Executive Director, Corporate Development
Celerion, Inc. John is based in Berlin and is a member of AHPPI.

Comments Off on AGAH Meeting, Berlin